28
Jun
2018
How Are Biotech VC Funds Performing? See Data From Five State Pension Funds
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jun
2018
How Are Biotech’s VCs Performing? Not As Well As You May Think
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jun
2018
Sarepta’s Stunner, Summer IPO Wave, and a White House Plan to Clip Wings at FDA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Jun
2018
Impact in More Ways Than One: Tony Coles on The Long Run Podcast
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Jun
2018
Bluebird Gene Therapy Holding Up, CRISPR Gyrations, and a Clever Antibiotic Business Idea
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jun
2018
EHA18 Preview: Blood Drugs to Watch in Stockholm
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jun
2018
BIO18 Reflections, Axovant and Ophthotech Reboot with Gene Therapy & More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Jun
2018
From Hoop Dreams to the Biopharma Big Time: Rob Perez on The Long Run
Today’s guest on the show is Rob Perez. He grew up in a lower-middle class household in Los Angeles. Had some hoop dreams that never quite materialized. No big deal. Perez found he had a knack for sales, and paid his way through college by working at fitness centers. Chance brought him into the pharmaceutical sales business. He liked meeting... Read More
23
May
2018
Re-Starting a Company, Keeping Hope Alive: Chip Clark on The Long Run
Today’s guest on The Long Run is Chip Clark. He’s the CEO of Cambridge, Mass.-based Genocea Biosciences. This vaccine platform company got into a jam last summer. It completed a Phase II trial with its lead therapeutic vaccine for genital herpes. Clark tried to insist the trial was a success and the product had a future. The market disagreed. The... Read More
9
May
2018
Charting His Own Entrepreneurial Course: Ethan Perlstein on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Apr
2018
What Can You Do With Genomics and AI? Alice Zhang on The Long Run
Today’s guest on The Long Run podcast is Alice Zhang. Let’s start with some basic background. Zhang studied systems biology at Princeton, graduated with honors, enrolled in an MD/PHD program at UCLA/Caltech, stayed there five years, quit, moved to Silicon Valley, and co-founded a company dedicated to using her knowledge for neurodegenerative drug discovery. She has been named among the... Read More
11
Apr
2018
The Immune Sequencing Frontier: Harlan and Chad Robins on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Mar
2018
Teaching and Mentoring the Next Generation: Vicki Sato on The Long Run Podcast
Today’s guest on The Long Run podcast is Vicki Sato. She’s one of the biotech industry’s pioneers. Sato started out as a classic academic scientist on the Harvard faculty. Beginning in the mid-1980s, and for about 20 years, the next phase of her career was as an executive at Biogen and Vertex Pharmaceuticals. Her fingerprints are all over a number... Read More
26
Mar
2018
Mt. Everest: It’s Time
Six months of hard training is in the bank. Tomorrow morning, I will lug a pair of 120-liter gear bags to the airport and get on the plane for Kathmandu. Destination: Mt. Everest, 29,029 feet/8,848 meters. The summit of the highest mountain in the world. No matter what happens, three things are certain: I’ve given it everything I’ve got to prepare... Read More
23
Mar
2018
The Data Wake-Up, AbbVie’s $5.8B Whiff, and a Regeneron-Alnylam Alliance
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Mar
2018
TCR2 Therapeutics Grabs $125M to Take TCR Therapies, Sans HLA Screens, To the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Mar
2018
Shkreli Goes to Jail, Holmes Gets Fined, & Gilead CSO Exits With Barely a Peep
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Mar
2018
From Rock DJ to Scientist to Entrepreneur: Michael Gilman on The Long Run Podcast
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Mar
2018
Photo Gallery: The Boston Cancer Summit
What a whirlwind last week was! The Seattle and Boston Cancer Summits were an East-West combo punch on behalf of the Everest Climb to Fight Cancer fundraising campaign for Fred Hutch. These events did the job: Bringing together leading thinkers and doers on both coasts, they both drew sellout, highly engaged crowds. The fundraising tally now stands at $326,000!! The... Read More
12
Mar
2018
Photo Gallery: The Seattle Cancer Summit
What a whirlwind last week was! The Seattle and Boston Cancer Summits were an East-West combo punch on behalf of the Everest Climb to Fight Cancer fundraising campaign for Fred Hutch. These events did the job: Bringing together leading thinkers and doers on both coasts, they both drew sellout, highly engaged crowds. The fundraising tally now stands at $326,000!! The... Read More